Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.

doi:10.1016/j.humpath.2017.02.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.

Human pathology - 1 Aug 2017

Shimada Yoshifumi, Yagi Ryoma, Kameyama Hitoshi, Nagahashi Masayuki, Ichikawa Hiroshi, Tajima Yosuke, Okamura Takuma, Nakano Mae, Nakano Masato, Sato Yo, Matsuzawa Takeaki, Sakata Jun, Kobayashi Takashi, Nogami Hitoshi, Maruyama Satoshi, Takii Yasumasa, Kawasaki Takashi, Homma Kei-Ichi, Izutsu Hiroshi, Kodama Keisuke, Ring Jennifer E, Protopopov Alexei, Lyle Stephen, Okuda Shujiro, Akazawa Kohei, Wakai Toshifumi

Abstract excerpt

HER2-targeted therapy is considered effective for KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (CRC). In general, HER2 status is determined by the use of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Comprehensive genomic sequencing (CGS) enables the detection of gene mutations and copy number alterations including KRAS mutation and HER2 amplification;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to In Situ Hybridization, Fluorescence

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Precision Medicine

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, ErbB-2

Source

Open in PubMed

Identifiers

PMID: 28235632
DOI: 10.1016/j.humpath.2017.02.004

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.PMID 28235632Read ↗

Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal CarcinomaSemantic proximity Read ↗

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.Semantic proximity Read ↗

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.Semantic proximity Read ↗

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma.Semantic proximity Read ↗

KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer.Semantic proximity Read ↗

Clinical utility of comprehensive genomic profiling test for colorectal cancer: A single institution prospective observational studySemantic proximity Read ↗

HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic SchemesSemantic proximity Read ↗

Investigating incidence of RAS/RAF and PIK3CA alterations in HER2-amplified colorectal cancer: a comprehensive analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.